Literature DB >> 32387451

Pre-mRNA splicing defects and RNA binding protein involvement in Niemann Pick type C disease.

Francesca Paron1, Andrea Dardis2, Emanuele Buratti3.   

Abstract

Niemann-Pick type C (NPC) is an autosomal recessive lysosomal storage disorder due to mutations in NPC1 (95 % cases) or NPC2 genes, encoding NPC1 and NPC2 proteins, respectively. Both NPC1 and NPC2 proteins are involved in transport of intracellular cholesterol and their alteration leads to the accumulation of unesterified cholesterol and other lipids within the lysosomes. The disease is characterized by visceral, neurological and psychiatric symptoms. However, the pathogenic mechanisms that lead to the fatal neurodegeneration are still unclear. To date, several mutations leading to the generation of aberrant splicing variants or mRNA degradation in NPC1 and NPC2 genes have been reported. In addition, different lines of experimental evidence have highlighted the possible role of RNA-binding proteins and RNA-metabolism, in the onset and progression of many neurodegenerative disorders, that could explain NPC neurological features and in general, the disease pathogenesis. In this review, we will provide an overview of the impact of mRNA processing and metabolism on NPC disease pathology.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Neurodegeneration; Niemann-Pick type C; RNA-binding proteins; RNA-metabolism; RNA-processing events; Therapeutic strategies

Year:  2020        PMID: 32387451     DOI: 10.1016/j.jbiotec.2020.03.012

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  2 in total

Review 1.  Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease.

Authors:  Ettaib El Marabti; Omar Abdel-Wahab
Journal:  Trends Mol Med       Date:  2021-05-13       Impact factor: 15.272

Review 2.  The Cerebellum in Niemann-Pick C1 Disease: Mouse Versus Man.

Authors:  Maria Teresa Fiorenza; Piergiorgio La Rosa; Sonia Canterini; Robert P Erickson
Journal:  Cerebellum       Date:  2022-01-18       Impact factor: 3.648

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.